Movement Alert｜WUXI XDC Rises 3.01% in Regular Trading, Sector Rebound Coupled with New Strategic Investment Expansion

Market Focus

Yesterday

On September 30, WUXI XDC rose 3.01% in regular trading, trading at 80.75 HKD/share, with turnover of 32.52 million HKD. The stock rebounded sharply after consecutive sessions of pressure earlier in the week.

On the news front, the company announced a new external investment, acquiring a 60.67% stake in Dongyao Pharmaceutical Co., Ltd., further expanding its ADC-related CDRDMO business footprint. The move reinforces the company's position as a global leader in antibody-drug conjugate development and manufacturing services.

Sector-wide, the Life Sciences Tools & Services industry staged a collective rebound after sustained selling pressure in prior sessions. Peer stocks rallied in tandem, with GenScript Biotech up 6.28%, Insilico Intelligence up 3.88%, WuXi Biologics up 2.34%, and WuXi AppTec up 1.64%, reflecting broad improvement in market sentiment across the CDMO segment. Goldman Sachs recently reiterated a Buy rating on the stock with a target price of 97.9 HKD, citing upcoming FDA inspection of the Wuxi production facility as a key commercial milestone.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1120698940"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120698940\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120698940?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120698940","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WUXI XDC Rises 3.01% in Regular Trading, Sector Rebound Coupled with New Strategic Investment Expansion","media":"Market Focus","content":"<p><p>On September 30, WUXI XDC rose 3.01% in regular trading, trading at 80.75 HKD/share, with turnover of 32.52 million HKD. The stock rebounded sharply after consecutive sessions of pressure earlier in the week.</p><p>On the news front, the company announced a new external investment, acquiring a 60.67% stake in Dongyao Pharmaceutical Co., Ltd., further expanding its ADC-related CDRDMO business footprint. The move reinforces the company's position as a global leader in antibody-drug conjugate development and manufacturing services.</p><p>Sector-wide, the Life Sciences Tools & Services industry staged a collective rebound after sustained selling pressure in prior sessions. Peer stocks rallied in tandem, with GenScript Biotech up 6.28%, Insilico Intelligence up 3.88%, WuXi Biologics up 2.34%, and WuXi AppTec up 1.64%, reflecting broad improvement in market sentiment across the CDMO segment. Goldman Sachs recently reiterated a Buy rating on the stock with a target price of 97.9 HKD, citing upcoming FDA inspection of the Wuxi production facility as a key commercial milestone.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WUXI XDC Rises 3.01% in Regular Trading, Sector Rebound Coupled with New Strategic Investment Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WUXI XDC Rises 3.01% in Regular Trading, Sector Rebound Coupled with New Strategic Investment Expansion\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-09-30 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On September 30, WUXI XDC rose 3.01% in regular trading, trading at 80.75 HKD/share, with turnover of 32.52 million HKD. The stock rebounded sharply after consecutive sessions of pressure earlier in the week.</p><p>On the news front, the company announced a new external investment, acquiring a 60.67% stake in Dongyao Pharmaceutical Co., Ltd., further expanding its ADC-related CDRDMO business footprint. The move reinforces the company's position as a global leader in antibody-drug conjugate development and manufacturing services.</p><p>Sector-wide, the Life Sciences Tools & Services industry staged a collective rebound after sustained selling pressure in prior sessions. Peer stocks rallied in tandem, with GenScript Biotech up 6.28%, Insilico Intelligence up 3.88%, WuXi Biologics up 2.34%, and WuXi AppTec up 1.64%, reflecting broad improvement in market sentiment across the CDMO segment. Goldman Sachs recently reiterated a Buy rating on the stock with a target price of 97.9 HKD, citing upcoming FDA inspection of the Wuxi production facility as a key commercial milestone.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1120698940","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120698940","pubTimestamp":1790732163,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, WUXI XDC rose 3.01% in regular trading, trading at 80.75 HKD/share, with turnover of 32.52 million HKD. The stock rebounded sharply after consecutive sessions of pressure earlier in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"走势提醒|无锡XDC常规交易上涨3.01%，板块反弹叠加新战略投资扩张","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On September 30, WUXI XDC rose 3.01% in regular trading, trading at 80.75 HKD/share, with turnover of 32.52 million HKD. The stock rebounded sharply after consecutive sessions of pressure earlier in the week.On the news front, the company announced a new external investment, acquiring a 60.67% stake in Dongyao Pharmaceutical Co., Ltd., further expanding its ADC-related CDRDMO business footprint. The move reinforces the company's position as a global leader in antibody-drug conjugate development and manufacturing services.Sector-wide, the Life Sciences Tools & Services industry staged a collective rebound after sustained selling pressure in prior sessions. Peer stocks rallied in tandem, with GenScript Biotech up 6.28%, Insilico Intelligence up 3.88%, WuXi Biologics up 2.34%, and WuXi AppTec up 1.64%, reflecting broad improvement in market sentiment across the CDMO segment. Goldman Sachs recently reiterated a Buy rating on the stock with a target price of 97.9 HKD, citing upcoming FDA inspection of the Wuxi production facility as a key commercial milestone.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}